Expansion
Efferon Registers Sepsis Blood Purification Device in India Through Helmier Partnership
By News Desk ·
Key takeaways
- Efferon AG registered its Efferon LPS blood purification device in India through a partnership with Helmier.
- Helmier will handle regulatory support, imports, supply, distribution and healthcare professional training for Efferon products.
- Efferon's technology has delivered more than 30,000 treatments across 45 countries, including Australia, the UK, Germany and Saudi Arabia.
Efferon AG has registered its Efferon LPS blood purification device in India and entered the market through a partnership with medical devices maker Helmier, Fortune India reported on November 18, 2026. The Austrian biotech company supplies devices for critical care involving severe sepsis and systemic inflammation.
How the Helmier Partnership Works
Under the partnership, Helmier will handle regulatory support, imports, supply and distribution of Efferon products, besides providing healthcare professional training, technical assistance and clinical support. Helmier will lead Efferon's market development in India, including regulatory activities, hospital outreach, product launch and ongoing service support.
The companies will combine product supplies with clinician training and on-ground technical support for Indian hospitals treating patients with severe sepsis and septic shock. "Efferon's devices will benefit India most when the launch is supported by hands-on training, reliable technical support," said Raghuram Iyer, co-founder and business unit head of Helmier.
Efferon, headquartered in Austria, has an office in the US and manufacturing facilities in Estonia and Latvia. Its technology is approved and used across Europe, with more than 30,000 treatments delivered across 45 countries, including Australia, the UK, Germany and Saudi Arabia. Helmier is a medical disposables and equipment manufacturer focused on anaesthesia, critical care and surgical solutions.
"Sepsis does not stop at borders. The pandemic made that painfully clear: estimated global cases of sepsis rose from 128 million in 2019 to 166 million in 2021," said Dima Romashin, CEO and co-founder of Efferon. He said the partnership would combine the company's technology and clinical experience with Helmier's understanding of the Indian hospital market.
Efferon's portfolio comprises two multimodal therapeutic hemoadsorption devices. Efferon LPS combines endotoxin and cytokine adsorption, enabling the simultaneous removal of bacterial endotoxins and excess inflammatory mediators from the bloodstream. The second product, Efferon NEO, is designed for neonates, children and adolescents with lower circulating blood volumes, and received the CE MDR mark in April 2026, supported by findings from the multicentre LASSO NEO study (NCT05707494), which evaluated the technology in children aged one month to 18 years.
Efferon's Funding and Regulatory Record
Efferon completed a $2.9 million financing round in May 2026, following a July 2021 Fix Ventures round of 200 million rubles (about $2.6 million), according to akta.pro company records. The same records show Efferon NEO received the EU MDR CE mark in April 2026, becoming Europe's first hemoadsorption device approved for neonatal and pediatric sepsis. Efferon LPS was incorporated into the updated German Society of Nephrology clinical guidelines for therapeutic apheresis in December 2025.
Earlier Efferon Milestones
Efferon raised €4.3 million in seed funding from DACH private investors, Startup Researcher reported in November 2026, with the company expecting intensive care products to reach €5 million in revenue by 2027. TechCrunch reported in October 2026 that Efferon NEO, developed for pediatric sepsis, received a CE mark in April and is used in 30 countries. In June 2026, CEO Dima Romashin told Axios Pro exclusively that Efferon was raising a $20 million Series A round for its pediatric sepsis device.
What Comes Next for Efferon in India
Helmier will lead Efferon's product launch in India and ongoing service support, according to Fortune India. Efferon NEO's CE MDR mark was received in April 2026.